 | • レポートコード：MRC2312MG09371 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、113ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥481,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥721,500 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のHER2腫瘍マーカー検査市場規模と予測を収録しています。・世界のHER2腫瘍マーカー検査市場：売上、2018年-2023年、2024年-2029年 ・世界のHER2腫瘍マーカー検査市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のHER2腫瘍マーカー検査市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「免疫組織化学（IHC）」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 HER2腫瘍マーカー検査のグローバル主要企業は、Abbott、 Roche、 Thermo Fisher Scientific、 Agilent、 Leica Biosystems、 Biocare Medical、 BioGenex、 Sysmex、 Abnova、 Novartis、 InvivoGenなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、HER2腫瘍マーカー検査のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のHER2腫瘍マーカー検査市場：タイプ別、2018年-2023年、2024年-2029年 世界のHER2腫瘍マーカー検査市場：タイプ別市場シェア、2022年 ・免疫組織化学（IHC）、蛍光その場ハイブリダイゼーション（FISH）、銀その場ハイブリダイゼーション（SISH）、その他 世界のHER2腫瘍マーカー検査市場：用途別、2018年-2023年、2024年-2029年 世界のHER2腫瘍マーカー検査市場：用途別市場シェア、2022年 ・病院、診断研究所、その他 世界のHER2腫瘍マーカー検査市場：地域・国別、2018年-2023年、2024年-2029年 世界のHER2腫瘍マーカー検査市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるHER2腫瘍マーカー検査のグローバル売上、2018年-2023年 ・主要企業におけるHER2腫瘍マーカー検査のグローバル売上シェア、2022年 ・主要企業におけるHER2腫瘍マーカー検査のグローバル販売量、2018年-2023年 ・主要企業におけるHER2腫瘍マーカー検査のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Abbott、 Roche、 Thermo Fisher Scientific、 Agilent、 Leica Biosystems、 Biocare Medical、 BioGenex、 Sysmex、 Abnova、 Novartis、 InvivoGen ************************************************************* ・調査・分析レポートの概要 HER2腫瘍マーカー検査市場の定義 市場セグメント 世界のHER2腫瘍マーカー検査市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のHER2腫瘍マーカー検査市場規模 世界のHER2腫瘍マーカー検査市場規模：2022年 VS 2029年 世界のHER2腫瘍マーカー検査市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのHER2腫瘍マーカー検査の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のHER2腫瘍マーカー検査製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：免疫組織化学（IHC）、蛍光その場ハイブリダイゼーション（FISH）、銀その場ハイブリダイゼーション（SISH）、その他 HER2腫瘍マーカー検査のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、診断研究所、その他 HER2腫瘍マーカー検査の用途別グローバル売上・予測 ・地域別市場分析 地域別HER2腫瘍マーカー検査市場規模 2022年と2029年 地域別HER2腫瘍マーカー検査売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Abbott、 Roche、 Thermo Fisher Scientific、 Agilent、 Leica Biosystems、 Biocare Medical、 BioGenex、 Sysmex、 Abnova、 Novartis、 InvivoGen ... |
This research report provides a comprehensive analysis of the HER2 Tumor Marker Testing market, focusing on the current trends, market dynamics, and future prospects. The report explores the global HER2 Tumor Marker Testing market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of HER2 Tumor Marker Testing, challenges faced by the industry, and potential opportunities for market players.
The global HER2 Tumor Marker Testing market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The HER2 Tumor Marker Testing market presents opportunities for various stakeholders, including Hospitals, Diagnostic Laboratories. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in HER2 Tumor Marker Testing market. Additionally, the growing consumer demand present avenues for market expansion.
The global HER2 Tumor Marker Testing market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
The global market for HER2 Tumor Marker Testing has been experiencing steady growth. This growth is primarily driven by the increasing incidence of breast cancer and the importance of HER2 status in determining treatment decisions. The market size is influenced by factors such as population aging, awareness of breast cancer screening, and advancements in diagnostic techniques. North America, particularly the United States, is a significant market for HER2 Tumor Marker Testing. The region has well-established breast cancer screening and diagnosis programs. The adoption of targeted therapies, such as Herceptin, has been prominent in this region. Europe also has a substantial market for HER2 testing, with countries like the United Kingdom, Germany, and France being key contributors. The European market is characterized by a growing emphasis on early cancer detection and personalized medicine. The Asia-Pacific region, including countries like China and India, offers growth opportunities. The increasing healthcare spending, growing awareness of breast cancer, and rising population contribute to market expansion.
Key Features:
The research report on the HER2 Tumor Marker Testing market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the HER2 Tumor Marker Testing market.
Market Overview: The report provides a comprehensive overview of the HER2 Tumor Marker Testing market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Immunohistochemistry (IHC), Fluorescence In Situ Hybridization (FISH)), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the HER2 Tumor Marker Testing market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the HER2 Tumor Marker Testing market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the HER2 Tumor Marker Testing market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the HER2 Tumor Marker Testing market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the HER2 Tumor Marker Testing market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the HER2 Tumor Marker Testing market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for HER2 Tumor Marker Testing, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the HER2 Tumor Marker Testing market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
HER2 Tumor Marker Testing market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Immunohistochemistry (IHC)
Fluorescence In Situ Hybridization (FISH)
Silver In Situ Hybridization (SISH)
Others
Market segment by Application
Hospitals
Diagnostic Laboratories
Others
Global HER2 Tumor Marker Testing Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Abbott
Roche
Thermo Fisher Scientific
Agilent
Leica Biosystems
Biocare Medical
BioGenex
Sysmex
Abnova
Novartis
InvivoGen
Outline of Major Chapters:
Chapter 1: Introduces the definition of HER2 Tumor Marker Testing, market overview.
Chapter 2: Global HER2 Tumor Marker Testing market size in revenue.
Chapter 3: Detailed analysis of HER2 Tumor Marker Testing company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of HER2 Tumor Marker Testing in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 HER2 Tumor Marker Testing Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global HER2 Tumor Marker Testing Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global HER2 Tumor Marker Testing Overall Market Size
2.1 Global HER2 Tumor Marker Testing Market Size: 2022 VS 2029
2.2 Global HER2 Tumor Marker Testing Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top HER2 Tumor Marker Testing Players in Global Market
3.2 Top Global HER2 Tumor Marker Testing Companies Ranked by Revenue
3.3 Global HER2 Tumor Marker Testing Revenue by Companies
3.4 Top 3 and Top 5 HER2 Tumor Marker Testing Companies in Global Market, by Revenue in 2022
3.5 Global Companies HER2 Tumor Marker Testing Product Type
3.6 Tier 1, Tier 2 and Tier 3 HER2 Tumor Marker Testing Players in Global Market
3.6.1 List of Global Tier 1 HER2 Tumor Marker Testing Companies
3.6.2 List of Global Tier 2 and Tier 3 HER2 Tumor Marker Testing Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global HER2 Tumor Marker Testing Market Size Markets, 2022 & 2029
4.1.2 Immunohistochemistry (IHC)
4.1.3 Fluorescence In Situ Hybridization (FISH)
4.1.4 Silver In Situ Hybridization (SISH)
4.1.5 Others
4.2 By Type – Global HER2 Tumor Marker Testing Revenue & Forecasts
4.2.1 By Type – Global HER2 Tumor Marker Testing Revenue, 2018-2023
4.2.2 By Type – Global HER2 Tumor Marker Testing Revenue, 2024-2029
4.2.3 By Type – Global HER2 Tumor Marker Testing Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global HER2 Tumor Marker Testing Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Diagnostic Laboratories
5.1.4 Others
5.2 By Application – Global HER2 Tumor Marker Testing Revenue & Forecasts
5.2.1 By Application – Global HER2 Tumor Marker Testing Revenue, 2018-2023
5.2.2 By Application – Global HER2 Tumor Marker Testing Revenue, 2024-2029
5.2.3 By Application – Global HER2 Tumor Marker Testing Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global HER2 Tumor Marker Testing Market Size, 2022 & 2029
6.2 By Region – Global HER2 Tumor Marker Testing Revenue & Forecasts
6.2.1 By Region – Global HER2 Tumor Marker Testing Revenue, 2018-2023
6.2.2 By Region – Global HER2 Tumor Marker Testing Revenue, 2024-2029
6.2.3 By Region – Global HER2 Tumor Marker Testing Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America HER2 Tumor Marker Testing Revenue, 2018-2029
6.3.2 US HER2 Tumor Marker Testing Market Size, 2018-2029
6.3.3 Canada HER2 Tumor Marker Testing Market Size, 2018-2029
6.3.4 Mexico HER2 Tumor Marker Testing Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe HER2 Tumor Marker Testing Revenue, 2018-2029
6.4.2 Germany HER2 Tumor Marker Testing Market Size, 2018-2029
6.4.3 France HER2 Tumor Marker Testing Market Size, 2018-2029
6.4.4 U.K. HER2 Tumor Marker Testing Market Size, 2018-2029
6.4.5 Italy HER2 Tumor Marker Testing Market Size, 2018-2029
6.4.6 Russia HER2 Tumor Marker Testing Market Size, 2018-2029
6.4.7 Nordic Countries HER2 Tumor Marker Testing Market Size, 2018-2029
6.4.8 Benelux HER2 Tumor Marker Testing Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia HER2 Tumor Marker Testing Revenue, 2018-2029
6.5.2 China HER2 Tumor Marker Testing Market Size, 2018-2029
6.5.3 Japan HER2 Tumor Marker Testing Market Size, 2018-2029
6.5.4 South Korea HER2 Tumor Marker Testing Market Size, 2018-2029
6.5.5 Southeast Asia HER2 Tumor Marker Testing Market Size, 2018-2029
6.5.6 India HER2 Tumor Marker Testing Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America HER2 Tumor Marker Testing Revenue, 2018-2029
6.6.2 Brazil HER2 Tumor Marker Testing Market Size, 2018-2029
6.6.3 Argentina HER2 Tumor Marker Testing Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa HER2 Tumor Marker Testing Revenue, 2018-2029
6.7.2 Turkey HER2 Tumor Marker Testing Market Size, 2018-2029
6.7.3 Israel HER2 Tumor Marker Testing Market Size, 2018-2029
6.7.4 Saudi Arabia HER2 Tumor Marker Testing Market Size, 2018-2029
6.7.5 UAE HER2 Tumor Marker Testing Market Size, 2018-2029
7 HER2 Tumor Marker Testing Companies Profiles
7.1 Abbott
7.1.1 Abbott Company Summary
7.1.2 Abbott Business Overview
7.1.3 Abbott HER2 Tumor Marker Testing Major Product Offerings
7.1.4 Abbott HER2 Tumor Marker Testing Revenue in Global Market (2018-2023)
7.1.5 Abbott Key News & Latest Developments
7.2 Roche
7.2.1 Roche Company Summary
7.2.2 Roche Business Overview
7.2.3 Roche HER2 Tumor Marker Testing Major Product Offerings
7.2.4 Roche HER2 Tumor Marker Testing Revenue in Global Market (2018-2023)
7.2.5 Roche Key News & Latest Developments
7.3 Thermo Fisher Scientific
7.3.1 Thermo Fisher Scientific Company Summary
7.3.2 Thermo Fisher Scientific Business Overview
7.3.3 Thermo Fisher Scientific HER2 Tumor Marker Testing Major Product Offerings
7.3.4 Thermo Fisher Scientific HER2 Tumor Marker Testing Revenue in Global Market (2018-2023)
7.3.5 Thermo Fisher Scientific Key News & Latest Developments
7.4 Agilent
7.4.1 Agilent Company Summary
7.4.2 Agilent Business Overview
7.4.3 Agilent HER2 Tumor Marker Testing Major Product Offerings
7.4.4 Agilent HER2 Tumor Marker Testing Revenue in Global Market (2018-2023)
7.4.5 Agilent Key News & Latest Developments
7.5 Leica Biosystems
7.5.1 Leica Biosystems Company Summary
7.5.2 Leica Biosystems Business Overview
7.5.3 Leica Biosystems HER2 Tumor Marker Testing Major Product Offerings
7.5.4 Leica Biosystems HER2 Tumor Marker Testing Revenue in Global Market (2018-2023)
7.5.5 Leica Biosystems Key News & Latest Developments
7.6 Biocare Medical
7.6.1 Biocare Medical Company Summary
7.6.2 Biocare Medical Business Overview
7.6.3 Biocare Medical HER2 Tumor Marker Testing Major Product Offerings
7.6.4 Biocare Medical HER2 Tumor Marker Testing Revenue in Global Market (2018-2023)
7.6.5 Biocare Medical Key News & Latest Developments
7.7 BioGenex
7.7.1 BioGenex Company Summary
7.7.2 BioGenex Business Overview
7.7.3 BioGenex HER2 Tumor Marker Testing Major Product Offerings
7.7.4 BioGenex HER2 Tumor Marker Testing Revenue in Global Market (2018-2023)
7.7.5 BioGenex Key News & Latest Developments
7.8 Sysmex
7.8.1 Sysmex Company Summary
7.8.2 Sysmex Business Overview
7.8.3 Sysmex HER2 Tumor Marker Testing Major Product Offerings
7.8.4 Sysmex HER2 Tumor Marker Testing Revenue in Global Market (2018-2023)
7.8.5 Sysmex Key News & Latest Developments
7.9 Abnova
7.9.1 Abnova Company Summary
7.9.2 Abnova Business Overview
7.9.3 Abnova HER2 Tumor Marker Testing Major Product Offerings
7.9.4 Abnova HER2 Tumor Marker Testing Revenue in Global Market (2018-2023)
7.9.5 Abnova Key News & Latest Developments
7.10 Novartis
7.10.1 Novartis Company Summary
7.10.2 Novartis Business Overview
7.10.3 Novartis HER2 Tumor Marker Testing Major Product Offerings
7.10.4 Novartis HER2 Tumor Marker Testing Revenue in Global Market (2018-2023)
7.10.5 Novartis Key News & Latest Developments
7.11 InvivoGen
7.11.1 InvivoGen Company Summary
7.11.2 InvivoGen Business Overview
7.11.3 InvivoGen HER2 Tumor Marker Testing Major Product Offerings
7.11.4 InvivoGen HER2 Tumor Marker Testing Revenue in Global Market (2018-2023)
7.11.5 InvivoGen Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer